Electrophysiologic Measures of Treatment Response in Alzheimer Disease
Information source: Department of Veterans Affairs
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Alzheimer Disease
Intervention: Aricept (Drug); Exelon (Drug); Nicoderm Patch (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Department of Veterans Affairs Official(s) and/or principal investigator(s): Vincente Iragui, M.D., Ph.D Shuanna Morris, Ph.D.
Summary
The main purpose of this study is to determine the electrophysiological effects of
cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer
disease. The attempt will be to locate electrophysiological markers and predictors of
cognitive and clinical treatment response.
Clinical Details
Official title: Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease
Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Eligibility
Minimum age: 55 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Patients diagnosed with mild to moderate probable Alzheimer's disease (mini-mental state
exam scores between 15-27), and normal controls (age generally between 60-85). Subjects
must either be planning to start daily cholinesterase therapy (e. g. Aricept, Exelon) or
willing to try a transdermal nicotine patch for two 8 hour periods.
Locations and Contacts
Department of Veterans Affairs, San Diego, California 92161, United States
Additional Information
Starting date: October 1998
Last updated: January 20, 2009
|